MerLion Pharmaceuticals Pte. Ltd.
MerLion Pharmaceuticals Pte. Ltd., a prominent player in the biopharmaceutical industry, is headquartered in Singapore (SG) and operates extensively across Asia and Europe. Founded in 2006, the company has made significant strides in developing innovative therapeutics, particularly in the fields of infectious diseases and oncology. MerLion is renowned for its unique portfolio of products, including novel antibiotics and anti-cancer agents, which are distinguished by their targeted mechanisms of action and commitment to addressing unmet medical needs. With a strong focus on research and development, the company has achieved notable milestones, positioning itself as a leader in the fight against drug-resistant infections. Through its dedication to advancing healthcare solutions, MerLion Pharmaceuticals continues to enhance its market presence and contribute to global health initiatives.
DitchCarbon Score
How does MerLion Pharmaceuticals Pte. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MerLion Pharmaceuticals Pte. Ltd.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MerLion Pharmaceuticals Pte. Ltd.'s reported carbon emissions
MerLion Pharmaceuticals Pte. Ltd., headquartered in Singapore (SG), currently does not report any carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established specific reduction targets or commitments under initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges. As a result, MerLion Pharmaceuticals has not disclosed any significant climate commitments or reduction initiatives at this time. The absence of emissions data and reduction targets suggests that the company may still be in the early stages of developing its climate strategy. In the broader context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, highlighting the importance of establishing clear climate commitments to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MerLion Pharmaceuticals Pte. Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
